Profile Name
Profile desiganation
Profile Content
Coming Soon...
Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous allogeneic mesenchymal stem cells in this population.
The Board of Directors of Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant stem cells, announced today that it has appointed Michael K. Steinhauser as Chief Executive Officer and Interim Chairman of...
SanoStem a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,…
Respected and seasoned business leader, investor and political strategist offers multiple talents to stem company SAN DIEGO, PRNewswire/ --SanoStem , Inc. ("SanoStem"), a San Diego-based biotech company...
Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — StemProtein, LLC (a subsidiary ofSanoStem , Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...
SanoStem("SanoStem"), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its study entitled "A Phase II,...